Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.77 |
| ▸ | MMP9 | P14780 | 1/20 | 0.77 |
| ▸ | MMP8 | P22894 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | GLA | P06280 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872727 | 0.88 | APP (1.00) | APPMMP9MMP8RAB9ANPC1 | |
| 2-Phenylbenzo[D]Thiazole SCHEMBL12479300 | 0.85 | APP (0.93) | APPMMP9MMP8RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL6283670 | 0.81 | APP (0.69) | APPMMP9MMP8TP53RAB9A | |
| SCHEMBL13853339 | 0.81 | APP (1.00) | APPMMP9MMP8TP53RAB9A | |
| SCHEMBL7109998 | 0.80 | TP53 (0.75) | APPMMP9MMP8TP53RAB9A | |
| SCHEMBL366824 | 0.79 | RAB9A (0.81) | APPMMP9MMP8TP53RAB9A | |
| SCHEMBL29474819 | 0.79 | RAB9A (0.81) | APPMMP9MMP8TP53RAB9A | |
| SCHEMBL12727647 | 0.79 | MMP9 (0.81) | APPMMP9MMP8TP53RAB9A | |
| 2-Phenylbenzo[D]Thiazole SCHEMBL10820979 | 0.79 | RAB9A (0.61) | APPMMP9MMP8TP53RAB9A | |
| Ammonia Solution, Strong SCHEMBL7106619 | 0.79 | TP53 (0.73) | APPMMP9MMP8TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | claimed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | claimed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5874431-A | ANTITUMOR AGENTS; BREAST CANCER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-02-23 | — | — | US | disclosed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | APP 24/4885MMP9 1535/4885MMP8 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.